Tattoo Sites and Psoriasis

October 2011 | Volume 10 | Issue 10 | Case Report | 1199 | Copyright © 2011

Samantha F. Smith BSa and Steven R. Feldman MD PhDa,b,c

Center for Dermatology Research, Departments of aDermatology, bPathology and,cPublic Health Sciences Wake Forest University School of Medicine, Winston-Salem, NC

Abstract

The Koebner phenomenon refers to the development of lesions in response to injury of previously uninvolved skin. It occurs in psoriasis and a number of other inflammatory diseases. We present a patient who developed a Koebner reaction at the site of a tattoo. Treatment with ustekinumab resulted in striking clearance of the psoriasis changes at the tattoo site.

J Drugs Dermatol. 2011;10(10:1199-1200.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

INTRODUCTION

The Koebner phenomenon refers to the development of lesions in previously uninvolved skin at the site of cutaneous injury, and has been reported in psoriasis patients after a variety of traumas, including excoriation, insect bites, shaving, stripping of tape, friction and even pressure.1-2 We present a robust, tattoo-induced Koebner reaction in a psoriasis patient with striking clearance after initiation of ustekinumab.

CASE REPORT

A 19-year-old Causcasian female presented to our clinic for follow-up management of chronic psoriasis. She complained of persistent flaring of her disease despite treatment with etanercept in combination with ultraviolet phototherapy. Since the time of her diagnosis approximately two years earlier, the patient had tried numerous psoriasis medications with minimal improvement. Systemic treatment was initiated shortly after her diagnosis, as she presented with fairly severe disease that was not well-controlled with a topical corticosteroid. The patient had failed previous treatment with methotrexate and adalimumab, and was not responding to several months of etanercept treatment when she arrived for follow-up evaluation. On physical examination, she had active, erythematous and scaly psoriasiform lesions on her eyelids, face, trunk and extremities. On her back, psoriatic plaques were distributed in a tattoo that the patient had acquired four months earlier (Figure 1a). The Psoriasis Area and Severity Index (PASI) was 18.9.

Although the patient had rather extensive disease that affected many areas of her body, she maintains that her back was free of disease when she obtained the tattoo. Within 1-2 weeks of obtaining the tattoo, psoriatic lesions developed where the ink had been injected, which persisted until her appointment four months later.

Given the failure of other agents, ustekinumab treatment was initiated. When the patient returned one month after having the first and only dose of ustekinumab, she reported the greatest improvement she had experienced since her diagnosis. Most areas that had active disease at the previous appointment had improved considerably (PASI improved to 6.8), with complete clearance of the lesions that had been present at her tattoo site (Figure 1b).

DISCUSSION

Approximately 25 percent of psoriasis patients exhibit koebnerization,2 yet the pathogenesis of this phenomenon is not well understood. Some studies suggest there is a much higher prevalence of koebnerization (up to 95%) in patients who, like our patient, were diagnosed at an early age and had been tried on multiple therapies.3 Moreover, psoriasis that koebnerizes has been speculated to represent a more severe, treatment-resistant disease.4 Our patient was fortunate to have initial success with ustekinumab, although the long-term outcome remains to be seen. Ustekinumab has not been studied specifically in

↑ back to top


  • 1
  • 2

Related Articles